```html

Amyloidosis – Comprehensive Medical Guide

Overview

Amyloidosis is a rare group of diseases characterized by the abnormal accumulation of misfolded protein fibrils—called amyloid—in organs and tissues. These fibrils deposit extracellularly, disrupting normal structure and function. The condition can affect virtually any organ, but the most common forms involve the heart, kidneys, liver, nervous system, and gastrointestinal tract.

Who it affects: Amyloidosis can occur at any age, but most diagnoses are made in adults between 50 and 70 years. Men are slightly more likely than women to develop certain types (e.g., AL amyloidosis), whereas others (e.g., hereditary transthyretin‑related amyloidosis) affect both sexes equally.

Prevalence: Because the disease is heterogeneous and often under‑diagnosed, exact numbers are uncertain. In the United States, an estimated 1–9 cases per million people are diagnosed each year for systemic AL amyloidosis, making it a rare disease. Transthyretin (ATTR) amyloidosis is slightly more common, with ~5,000–10,000 new cases reported annually in the U.S. and Europe combined.<sup>1</sup>

Symptoms

The clinical picture varies widely depending on the organ(s) involved and the type of amyloid protein. Below is a comprehensive list grouped by system:

Cardiac (Heart) Symptoms

• Shortness of breath on exertion or at rest.
• Fatigue and reduced exercise tolerance.
• Orthopnea (difficulty breathing when lying flat).
• Peripheral edema (swelling of ankles/feet).
• Palpitations or irregular heartbeats.
• Syncope (fainting) due to low cardiac output.

Renal (Kidney) Symptoms

• Proteinuria (protein in urine) – often the first clue.
• Edema in legs or around the eyes.
• Decreased urine output.
• Elevated serum creatinine or reduced glomerular filtration rate (GFR).

Gastrointestinal Symptoms

• Early satiety and feeling full after small meals.
• Nausea, vomiting, or chronic diarrhea.
• Weight loss.
• Unexplained gastrointestinal bleeding.

Neurologic Symptoms

• Peripheral neuropathy – tingling, numbness, or burning pain in hands/feet.
• Autonomic dysfunction – orthostatic hypotension, gastrointestinal motility issues, erectile dysfunction.
• Carpal tunnel syndrome (often an early sign of ATTR).
• Cognitive changes (rare).

Hepatic (Liver) Symptoms

• Hepatomegaly (enlarged liver) detected on exam or imaging.
• Elevated liver enzymes (alkaline phosphatase, γ‑GT).
• Jaundice (uncommon).

Other Systemic Signs

• Macroglossia (enlarged tongue) – classic for AL amyloidosis.
• Skin changes: purpura around eyes (periorbital purpura) or easy bruising.
• Joint pain or stiffness.
• Unexplained weight loss and generalized weakness.

Causes and Risk Factors

Amyloidosis is not a single disease; it represents a spectrum of disorders defined by the type of amyloid protein involved. The most common types are:

• AL (light‑chain) amyloidosis: Produced by abnormal clones of plasma cells that secrete monoclonal light chains. Often associated with plasma‑cell dyscrasias such as multiple myeloma.
• ATTR (transthyretin) amyloidosis:
  • Hereditary (mutated TTR gene) – inherited in an autosomal‑dominant pattern; >120 mutations identified.
  • Wild‑type (formerly “senile systemic”) – age‑related deposition of normal transthyretin, most common in men >70 years.
• Amyloid A (AA) amyloidosis: Chronic inflammatory conditions (e.g., rheumatoid arthritis, inflammatory bowel disease, chronic infections) trigger high serum amyloid A protein levels that can deposit.
• Other rare forms: β2‑microglobulin amyloidosis (dialysis‑related), hereditary apolipoprotein A‑I, and others.

Risk Factors

• Age > 50 (especially for wild‑type ATTR).
• Male sex – higher prevalence of wild‑type ATTR.
• Family history of hereditary ATTR or other amyloidogenic mutations.
• Chronic inflammatory or infectious diseases (e.g., rheumatoid arthritis, tuberculosis, chronic osteomyelitis) → higher AA‑amyloidosis risk.
• Plasma‑cell disorders (MGUS, multiple myeloma) → increased AL‑amyloidosis risk.
• Long‑term hemodialysis (>5 years) – risk for β2‑microglobulin amyloidosis.

Diagnosis

Because symptoms are often nonspecific, a high index of suspicion is required. Diagnosis proceeds in three steps: suspecting the disease, confirming amyloid deposition, and typing the amyloid protein.

Initial Evaluation

• Detailed medical history and physical exam focusing on organ‑specific signs.
• Baseline laboratory panel: CBC, CMP, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP) with immunofixation, serum free light‑chain assay.
• Imaging tailored to symptoms: echocardiogram, cardiac MRI, abdominal ultrasound, or CT.

Definitive Tests

1. Biopsy
   • Gold‑standard: tissue sample stained with Congo red shows apple‑green birefringence under polarized light.
   • Site selection: abdominal fat‑pad aspirate is minimally invasive and yields a diagnosis in ~70 % of systemic cases. If negative and suspicion remains, organ‑specific biopsies (e.g., endomyocardial, renal, or liver) are performed.
2. Amyloid typing
   • Mass spectrometry–based proteomics (preferred).
   • Immunohistochemistry or immunoelectron microscopy when mass spectrometry unavailable.
3. Cardiac evaluation
   • Echocardiogram – shows concentric ventricular thickening with a “sparkling” appearance.
   • Cardiac MRI – late gadolinium enhancement pattern typical for amyloid.
   • Technetium‑99m pyrophosphate (PYP) scan – high uptake suggests ATTR, helping differentiate from AL.
4. Renal assessment
   • 24‑hour urine protein quantification.
   • Kidney biopsy if proteinuria >1 g/day and diagnosis remains uncertain.
5. Neurologic testing
   • Nerve conduction studies for peripheral neuropathy.
   • Autonomic function testing (e.g., tilt‑table test).

Early involvement of a multidisciplinary team—cardiology, hematology/oncology, nephrology, neurology, and genetics—is essential for accurate typing and staging.

Treatment Options

Treatment strategies differ markedly by amyloid type and organ involvement. The overarching goals are to halt further amyloid production, remove existing deposits when possible, and support affected organs.

AL Amyloidosis

• Plasma‑cell directed therapy
  • Combination regimens: CyBorD (cyclophosphamide + bortezomib + dexamethasone) is first‑line.
  • High‑dose melphalan with autologous stem‑cell transplant (ASCT) for eligible patients (<65 y, good organ function).
• Targeted agents
  • Daratumumab (anti‑CD38) – approved for relapsed AL amyloidosis (2023).
  • Venetoclax (BCL‑2 inhibitor) – emerging data for t(11;14) clones.
• Supportive care
  • Diuretics for volume overload.
  • Renin‑angiotensin‑aldosterone system (RAAS) blockers for proteinuria.

ATTR Amyloidosis

• TTR stabilizers
  • Tafamidis (Vyndaqel) – improves survival in both wild‑type and hereditary ATTR cardiomyopathy (FDA‑approved 2019).
  • Diflunisal (off‑label) – non‑steroidal anti‑inflammatory that binds TTR.
• TTR gene‑silencing therapies
  • Patisiran (siRNA) – administered intravenously every 3 weeks; shown to improve neuropathy scores.
  • Inotersen (antisense oligonucleotide) – subcutaneous weekly; effective for hereditary ATTR polyneuropathy.
• Liver transplantation (historical) – replaces mutant TTR source; now rarely first‑line because of effective gene‑silencing drugs.

AA Amyloidosis

• Control of underlying inflammatory disease (e.g., biologic agents for rheumatoid arthritis, anti‑TNF therapy).
• Eculizumab (complement inhibitor) – investigational for refractory cases.

General Supportive Measures

• Cardiac – beta‑blockers, ACE inhibitors, or ARBs as tolerated; consider implantable cardioverter‑defibrillator (ICD) if ventricular arrhythmias.
• Renal – ACEi/ARB for proteinuria; dialysis when eGFR <15 mL/min/1.73 m².
• Neurologic – gabapentin or duloxetine for neuropathic pain; physical therapy.
• Nutritional – low‑salt diet for heart failure; calorie‑dense meals if GI malabsorption.

Living with Amyloidosis

Managing a chronic, multisystem disease requires a coordinated approach:

• Regular follow‑up: Every 3–6 months with the primary specialist (hematology for AL, cardiology for ATTR). Labs (NT‑proBNP, troponin, free light chains) guide disease activity.
• Medication adherence: Missing doses of tafamidis or gene‑silencing agents can lead to rapid progression.
• Symptom monitoring: Keep a log of weight, swelling, shortness of breath, and neuropathic pain.
• Exercise: Low‑impact activities (walking, stationary cycling, yoga) improve functional capacity without overtaxing the heart.
• Dietary considerations:
  • Heart‑friendly – limit sodium to <2 g/day, avoid excess alcohol.
  • Kidney‑friendly – moderate protein, avoid high‑potassium foods if eGFR <30.
  • GI‑friendly – small, frequent meals; consider pancreatic enzyme supplements if malabsorption is evident.
• Psychosocial support: Join support groups (e.g., Amyloidosis Foundation), seek counseling for anxiety/depression that often accompanies chronic illness.
• Vaccinations: Annual influenza, COVID‑19 boosters, and pneumococcal vaccines are recommended, especially for patients receiving immunosuppressive therapy.

Prevention

Because many forms are genetically determined or stem from unavoidable protein misfolding, primary prevention is limited. However, risk can be mitigated by:

• Managing chronic inflammatory conditions aggressively (biologics, disease‑modifying agents).
• Screening family members when a hereditary ATTR mutation is identified; early genetic counseling allows surveillance and timely treatment.
• Regular monitoring of patients with plasma‑cell disorders for early signs of light‑chain production.
• Adhering to dialysis protocols that reduce β2‑microglobulin buildup (high‑flux membranes, frequent exchanges).

Complications

If left untreated or inadequately controlled, amyloidosis can lead to serious, often life‑threatening complications:

• Heart failure – progressive restrictive cardiomyopathy; common cause of death in ATTR and AL.
• Arrhythmias – atrial fibrillation, ventricular tachycardia, sudden cardiac death.
• Renal failure – end‑stage kidney disease requiring dialysis or transplantation.
• Peripheral neuropathy – severe pain, loss of sensation, risk of falls and injuries.
• Gastrointestinal bleeding – due to mucosal fragility.
• Thromboembolic events – atrial stasis in amyloid cardiomyopathy increases clot risk.
• Infection – immunosuppressive treatments raise susceptibility.

When to Seek Emergency Care

---

References:
1. Gertz, M. A. et al. “AL Amyloidosis: Diagnosis and Treatment.” Mayo Clinic Proceedings, 2022.
2. Falk, R. H. et al. “Transthyretin Amyloidosis.” New England Journal of Medicine, 2023.
3. National Institute of Health. “Amyloidosis Overview.” NIH Rare Diseases Information Center, 2024.
4. American Heart Association. “Cardiac Amyloidosis.” AHA Scientific Statements, 2023.
5. CDC. “Rare Disease Statistics.” 2024.
6. Cleveland Clinic. “Amyloidosis – Symptoms and Treatment.” 2024.

```